Adaptive Immunotherapy for Locoregional Nasopharyngeal Carcinoma: a Randomized, Controlled, Multicenter, Phase 3 Clinical Trial
Latest Information Update: 10 Dec 2025
At a glance
- Drugs Toripalimab (Primary) ; Capecitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 25 Nov 2025 Status changed from not yet recruiting to recruiting.
- 15 Sep 2025 New trial record